JP2025513929A - がんの処置のためのｒａｓ阻害剤とファルネシルトランスフェラーゼ阻害剤との組合せ - Google Patents

がんの処置のためのｒａｓ阻害剤とファルネシルトランスフェラーゼ阻害剤との組合せ Download PDF

Info

Publication number
JP2025513929A
JP2025513929A JP2024563327A JP2024563327A JP2025513929A JP 2025513929 A JP2025513929 A JP 2025513929A JP 2024563327 A JP2024563327 A JP 2024563327A JP 2024563327 A JP2024563327 A JP 2024563327A JP 2025513929 A JP2025513929 A JP 2025513929A
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
ras
subject
farnesyltransferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513929A5 (https=
Inventor
カルヴァイラク，オリヴィエ
ファーブル，ジル
ドライエ，セリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
INSTITUT CLAUDIUS REGAUD
Universite de Toulouse
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
INSTITUT CLAUDIUS REGAUD
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, INSTITUT CLAUDIUS REGAUD, Universite Toulouse III Paul Sabatier filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2025513929A publication Critical patent/JP2025513929A/ja
Publication of JP2025513929A5 publication Critical patent/JP2025513929A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024563327A 2022-04-28 2023-04-27 がんの処置のためのｒａｓ阻害剤とファルネシルトランスフェラーゼ阻害剤との組合せ Pending JP2025513929A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22305636 2022-04-28
EP22305636.7 2022-04-28
EP22306602.8 2022-10-21
EP22306602 2022-10-21
PCT/EP2023/061079 WO2023209073A1 (en) 2022-04-28 2023-04-27 Combination of ras inhibitors and farnesyltransferase inhibitors for the treatment of cancers

Publications (2)

Publication Number Publication Date
JP2025513929A true JP2025513929A (ja) 2025-04-30
JP2025513929A5 JP2025513929A5 (https=) 2026-04-28

Family

ID=86378289

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563327A Pending JP2025513929A (ja) 2022-04-28 2023-04-27 がんの処置のためのｒａｓ阻害剤とファルネシルトランスフェラーゼ阻害剤との組合せ

Country Status (5)

Country Link
US (1) US20250262211A1 (https=)
EP (1) EP4514356A1 (https=)
JP (1) JP2025513929A (https=)
KR (1) KR20250002557A (https=)
WO (1) WO2023209073A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719410A1 (en) * 2023-05-31 2026-04-08 Kura Oncology, Inc. Farnesyltransferase inhibitors for treatment of kras-dependent cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335077A1 (en) * 2013-05-07 2014-11-13 Leonard Girnita Compositions and Methods for the Treatment of Cancer Using IGF-IR Antagonists and MAPK/ERK Inhibitors
US11331312B2 (en) * 2014-04-25 2022-05-17 Memorial Sloan-Kettering Cancer Center Treatment of H-Ras-driven tumors
US20230285498A1 (en) * 2020-08-07 2023-09-14 City Of Hope Treatments for cancers having kras mutations

Also Published As

Publication number Publication date
WO2023209073A1 (en) 2023-11-02
US20250262211A1 (en) 2025-08-21
KR20250002557A (ko) 2025-01-07
EP4514356A1 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
CN110325191A (zh) 以较少的副作用治疗egfr-驱动的癌症
US20220401436A1 (en) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US20040167139A1 (en) Methods of treating cancer
BR112020023975A2 (pt) composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas
EP2433636A1 (en) Treatment of Malignant Diseases
JP2021525244A (ja) 腫瘍性疾患を治療するための薬剤の調製におけるｅｇｆｒ阻害剤と組み合わせたｃｄｋ４／６阻害剤の使用
Hwang et al. Carnosine exerts antitumor activity against bladder cancers in vitro and in vivo via suppression of angiogenesis
JP2021523190A (ja) 腺様嚢胞癌を治療するためのビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物
JP2025513929A (ja) がんの処置のためのｒａｓ阻害剤とファルネシルトランスフェラーゼ阻害剤との組合せ
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
JP2021063014A (ja) 白血病治療薬
JP6373252B2 (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
WO2019191493A1 (en) Cancer chemoprevention with stat3 blockers
EP3815709A1 (en) Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug
US20250368617A1 (en) Novel ras inhibitors
US20250186438A1 (en) Treatment of clear cell renal cell carcinoma
US12226454B2 (en) Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug
CN118829432A (zh) 用于治疗癌症的ras抑制剂和法尼基转移酶抑制剂的组合
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
US20250049807A1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
EP4536646A1 (en) Novel ras inhibitors
EP4536665A1 (en) Novel ras inhibitors
JP2022023033A (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
AU2023293888A1 (en) Mitoxanthrone derivatives as ras inhibitors
WO2023242103A1 (en) Novel ras inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260420